ipragliflozin

イプラグリフロジン

Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/06/20 16:16:30」(JST)

wiki en

[Wiki en表示]

Ipragliflozin

Systematic (IUPAC) name
(1S)-1,5-Anhydro-1-[3-(1-benzothiophen-2-ylmethyl)-4-fluorophenyl]-D-glucitol
Clinical data
Trade names	Suglat
Identifiers
PubChem	CID 10453870
ChemSpider	8629286
KEGG	D10196
ChEMBL	CHEMBL2018096
Chemical data
Formula	C21H21FO5S
Molar mass	404.45 g/mol
SMILES S1C(=CC2=C1C=CC=C2)CC=2C=C(C=CC2F)[C@H]2[C@H](O)[C@@H](O)[C@H](O)[C@H](O2)CO
InChI InChI=1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1 COPY Key:AHFWIQIYAXSLBA-RQXATKFSSA-N

Ipragliflozin (Suglat) is a pharmaceutical drug for treatment of type 2 diabetes. It was approved for use in Japan in 2014.

Ipragliflozin is an SGLT2 inhibitor.

References

English Journal

• Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes stratified by body mass index: A subgroup analysis of five randomized clinical trials.

• Kashiwagi A1, Yoshida S2, Nakamura I2, Kazuta K2, Ueyama E2, Takahashi H2, Satomi H2, Kosakai Y2, Kawamuki K2.
• Journal of diabetes investigation.J Diabetes Investig.2016 Jul;7(4):544-54. doi: 10.1111/jdi.12471. Epub 2016 Mar 1.
• AIMS/INTRODUCTION: The influence of overweight/obesity on the clinical efficacy and safety of sodium-glucose co-transporter 2 inhibitors is unclear. We carried out a pooled analysis to examine the impact of body mass index on the efficacy and safety of ipragliflozin.MATERIALS AND METHODS: Patient-le
• PMID 27181576

• Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy.

• Yamamoto C1, Miyoshi H, Ono K, Sugawara H, Kameda R, Ichiyama M, Yamamoto K, Nomoto H, Nakamura A, Atsumi T.
• Endocrine journal.Endocr J.2016 Jun 30;63(6):589-96. doi: 10.1507/endocrj.EJ15-0749. Epub 2016 Apr 6.
• To investigate if ipragliflozin, a novel sodium-glucose co-transporter 2 inhibitor, alters body composition and to identify variables associated with reductions in visceral adipose tissue in Japanese patients with type 2 diabetes mellitus. This prospective observational study enrolled Japanese parti
• PMID 27052123

• First case of drug eruption due to ipragliflozin: Case report and review of the literature.

• Saito-Sasaki N1, Sawada Y1, Nishio D1, Nakamura M1.
• The Australasian journal of dermatology.Australas J Dermatol.2016 May 31. doi: 10.1111/ajd.12502. [Epub ahead of print]
• Ipragliflozin is a new drug for the treatment of diabetes mellitus. Its action of sodium-glucose cotransporter 2 (SGLT2) inhibition induces glucosuria and decreases blood glucose levels. We report the first case of ipragliflozin-related eczematous drug eruption and a review of the past literature on
• PMID 27242192

Japanese Journal

• Fluctuation in Serum Sodium Levels Related to Ipragliflozin Administration in a Patient with Diabetic Nephropathy and Sequela of Traumatic Brain Injury

• Internal Medicine 55(14), 1887-1891, 2016
• NAID 130005164999

• Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

• Endocrine Journal 63(6), 589-596, 2016
• NAID 130005159561

• Ipragliflozin effectively reduced visceral fat in Japanese patients with type 2 diabetes under adequate diet therapy

• Endocrine Journal advpub(0), 2016
• NAID 130005143576

Related Pictures

---

★リンクテーブル★

リンク元	「イプラグリフロジン」

「イプラグリフロジン」

　　[★]

英

ipragliflozin

商

スーグラ

関

糖尿病、SGLT2

• 機序としては腎臓で原尿中に排出されたグルコースの再吸収をSGLT2を阻害することで抑制して血糖低下作用を期待する薬物。
• スーグラの場合1日50mg1回の服用でよい。